Idorsia Ltd
IDRSF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.03B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.03 Billion |
|---|---|
| Enterprise Value | $3.26 Billion |
| Earnings per Share | $-0.52 |
| Beta | 1.73 |
| Outstanding Shares | 255,900,000 |
Return
| Return on Equity | 26.53% |
|---|---|
| Return on Assets | -68.28% |
| Return on Invested Capital | -249.69% |
Valuation & Multiples
| P/E Ratio | -3.2 |
|---|---|
| PEG | -0.38 |
| Price to Sales | - |
| Price to Book Ratio | -1.08 |
| Enterprise Value to Revenue | 16.35 |
| Enterprise Value to EBIT | -16.51 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | -1.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.24
Consensus analyst estimateRevenue Estimate
$61.24 M
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.23
Consensus analyst estimateRevenue Estimate
$63.70 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Idorsia Ltd.
487 employees
CEO: Jean-Paul Clozel
Idorsia Ltd. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of medicines for medical needs. It operates through the following geographical segments: Switzerland, United States, Japan, a...